TAPINAROF

Course overview

THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED TAPINAROF IN MAY 2022 TO TREAT PLAQUE PSORIASIS IN ADULTS AGED 18 AND OLDER. TAPINAROF IS A NONSTEROIDAL, TOPICAL TREATMENT THAT BELONGS TO THE UNIQUE CLASS OF NATURALLY DERIVED ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS, DISTINGUISHING IT AS THE FIRST AGENT OF ITS KIND AND DIFFERENTIATING IT FROM STEROID-BASED TREATMENTS. PLAQUE PSORIASIS, A CHRONIC IMMUNE-MEDIATED DISEASE, REPRESENTS THE MOST COMMON SUBTYPE OF PSORIASIS. THIS ACTIVITY PROVIDES A COMPREHENSIVE REVIEW OF TAPINAROF, COVERING ITS INDICATIONS, MECHANISMS OF ACTION, AND ADMINISTRATION AS AN EFFECTIVE AGENT FOR MANAGING PLAQUE PSORIASIS ARE DISCUSSED. IN ADDITION, THE ACTIVITY DELVES INTO OFF-LABEL USES OF TAPINAROF, SUCH AS FOR TREATING ATOPIC DERMATITIS. VARIOUS ASPECTS OF TAPINAROF THERAPY, INCLUDING POSSIBLE ADVERSE EFFECTS, MONITORING, AND POTENTIAL CONTRAINDICATIONS. ALL INTERPROFESSIONAL HEALTHCARE TEAM MEMBERS SHOULD BE AWARE OF THIS INFORMATION AND POSSESS A GENERAL UNDERSTANDING OF TAPINAROF, AS IT IS CRUCIAL FOR TREATING ADULTS WITH PLAQUE PSORIASIS.